MIRA Advances SKNY-1 Oral Candidate with 6-12h Peak Plasma, Brain and Liver Exposure
MIRA•Preclinical studies of MIRA’s SKNY-1 oral formulation showed favorable bioavailability, robust brain penetration and substantial liver exposure, with peak plasma concentrations at six to twelve hours post-dose. These pharmacokinetic results support potential once-daily dosing and strengthen SKNY-1’s development profile for obesity and addiction therapy.
1. Preclinical Pharmacokinetic Findings
In preclinical pharmacokinetic studies, SKNY-1’s optimized oral formulation demonstrated favorable oral bioavailability and reproducible systemic exposure across multiple animals. The candidate achieved robust brain penetration and substantial liver exposure following a single oral dose, indicating reliable distribution into central nervous system and hepatic tissues relevant to appetite, reward signaling, and metabolic homeostasis.
2. Support for Once-Daily Dosing
Peak plasma concentrations of SKNY-1 were observed approximately six to twelve hours after dosing, aligning with a pharmacokinetic profile suitable for convenient once-daily administration. This extended absorption window may enhance patient adherence compared with more frequent dosing regimens common in obesity therapy.
3. Differentiated Mechanism and Safety Profile
SKNY-1 combines biased CB1 receptor modulation, partial CB2 agonism, and selective MAO-B inhibition to target metabolic and reward pathways. The compound’s robust brain penetration occurred without anxiety-related behaviors in preclinical models, suggesting a safer neuropsychiatric profile than earlier CB1-targeting drugs.
4. Next Steps in Development
MIRA plans to further explore the relationship between tissue exposure, pharmacodynamic activity, and therapeutic efficacy as SKNY-1 advances through additional preclinical development. These studies will support an investigational new drug application and eventual transition to first-in-human clinical trials.
